Skip to main content

Table 4 Blood pressure and biochemical data of patients at baseline compared with last assessment

From: Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective

Profile

n

TL-AA

TCGMP-AA

p value

Systolic blood pressure (mmHg)

11

112 ± 13

112 ± 11

1.000

Diastolic blood pressure (mmHg)

11

60 ± 15

63 ± 12

0.581

Heart rate (bpm)

11

73 ± 9

72 ± 8

0.607

Uric acid (mg/dL)

11

4.0 ± 0.8

4.0 ± 1.2

0.847

Glucose (mg/dL)

11

78.2 ± 6.8

75.6 ± 5.3

0.190

Creatinine (mg/dL)

11

0.7 ± 0.1

0.7 ± 0.1

0.676

Urea (mg/dL)

11

20.5 ± 7.6

23.2 ± 6.7

0.262

BUN (mg/dL)

11

1.68 ± 0.63

1.90 ± 0.55

0.268

HbA1c (%)

10

5.1 ± 0.4

5.0 ± 0.3

0.107

Total cholesterol (mg/dL)

11

165 ± 37

156 ± 34

0.349

HDL-C (mg/dL)

11

55 ± 14

51 ± 11

0.194

LDL-C (mg/dL)

11

93 ± 32

85 ± 32

0.265

VLDL-C (mg/dL)

11

17 ± 6

20 ± 10

0.121

Triglycerides (mg/dL)

11

84 ± 27

99 ± 50

0.140

ApoA1 (mg/dL)

10

153 ± 25

145 ± 31

0.187

ApoB (mg/dL)

10

82 ± 22

80 ± 22

0.612

Iron (μg/dL)

11

115 (85–135)

88 (48–144)

0.266

Transferrin (mg/dL)

11

271 ± 43

263 ± 44

0.554

Ferritin (ng/dL)

11

65 ± 35

52 ± 26

0.132

Albumin (g/dL)

11

4.69 ± 0.33

4.57 ± 0.17

0.112

Homocysteine (μmol/L)

8

8.44 ± 1.51

8.21 ± 1.32

0.820

Prealbumin (mg/dL)

11

240 (224–278)

272 (200–293)

0.575

CRP (mg/dL)

10

0.89 (0.72–2.46)

1.28 (0.77–2.92)

0.799

Insulin (μU/mL)

8

7.8 (7.3–13.6)

9.8 (6.5–18.3)

0.161

HOMA-IR

8

1.5 (1.4–2.5)

1.8 (1.2–3.5)

0.327

Calcium (mmol/L)

11

2.37 ± 0.12

2.33 ± 0.11

0.164

Phosphorus (mmol/L)

11

1.07 ± 0.24

0.98 ± 0.14

0.221

Selenium (μmol/L)

6

0.70 ± 0.30

0.96 ± 0.31

0.257

Zinc (μmol/L)

11

12.5 (9.7–17.4)

11.3 (10.4–12.4)

0.155

Vit. B12 (pg/L)

11

484 (413–734)

459 (301–1043)

0.722

Vit. D (nmol/L)

11

77 ± 26

70 ± 27

0.153

Folic acid (ng/mL)

9

12.9 ± 3.8

12.9 ± 5.3

0.996

  1. ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BUN, blood urea nitrogen; CGMP-AA, casein glycomacropeptide supplements; C, cholesterol; CRP, c-reactive protein; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein-cholesterol; HOMA-IR, homeostatic model of insulin resistance; L-AA, phenylalanine-free L-amino acid supplements; LDL-C, low-density lipoprotein-cholesterol; Phe, phenylalanine; PKU, phenylketonuria; Tyr, tyrosine; TL-AA, nutritional status evaluation under L-AA; TCGMP-AA, last annual nutritional status evaluation under CGMP-AA; Vit, vitamin; VLDL-C, very low-density lipoprotein-cholesterol. Data are presented as mean ± S.D. (n) or median (P25–P75) (n). Paired t-test and Wilcoxon test were performed to identify differences when normal distribution or non-normal was found, respectively. Significance was set at the level of p value less than 0.05